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Abstract
The endothelium, the monolayer covering the inner 
surface of blood vessels, plays a pivotal role in the regu-
lation of vascular tone and structure, as well as vascu-
lar inflammation and thrombosis, i.e., of key events of 
the atherosclerotic disease process and its clinical com-
plications, such as myocardial infarction and stroke. In 
particular a reduced endothelial availability of nitric 
oxide (NO), in part due to increased vascular oxidant 
stress, has been shown to promote a pro-inflammatory 
and prothrombotic phenotype of the endothelium. 
More recently, it has been observed that cardiovascular 
risk factors reduce the number and impair the function 
of circulating bone marrow-derived endothelial pro-
genitor cells (EPCs), thereby impairing the endogenous 
endothelial repair capacity.
Importantly, endothelial dysfunction has been 
identified as a common link of all cardiovascular risk 
factors. Numerous clinical studies have further dem-
onstrated a close association of the degree of endo-
thelial dysfunction with the risk of future cardiovas-
cular events. Whether endothelial dysfunction can 
improve cardiovascular risk prediction on top of a 
careful evaluation of classic cardiovascular risk fac-
tors is currently prospectively analyzed in several 
studies, i.e., in the PREVENT-it study. Furthermore, 
novel easier to use methods to assess endothelial 
function are currently explored, i.e., the Endo-PAT 
system, for their potential in improving cardiovascu-
lar risk prediction.
At present, assessment of endothelial function 
and EPCs are highly valuable research tools to improve 
our understanding of mechanisms of vascular disease 
and to determine the impact of novel therapeutic ap-
proaches on vascular function. Before endothelial 
function measurements can, however, be recommend-
ed in clinical practice for cardiovascular risk assess-
ment, the results of ongoing prospective studies as-
sessing the additive value of these measurements for 
cardiovascular risk prediction should be awaited.
Bedeutung der Endotheldysfunktion als Frühzeichen der Atherosklerose
 Zusammenfassung
Das Endothel, die einzellige Zellschicht, welche das Lu-
men der Blutgefäße auskleidet, spielt eine entschei-
dende Rolle bei der Regulation des Gefäßtonus und der 
Gefäßstruktur. Des Weiteren besitzt das „gesunde“ En-
dothel wichtige antiinflammatorische und antithrom-
botische Eigenschaften. Kardiovaskuläre Risikofakto-
ren führen insbesondere über eine verminderte Ver-
fügbarkeit des endothelial gebildeten Vasodilatators 
Stickstoffmonoxid (NO), zumindest z.T. als Folge einer 
gesteigerten vaskulären Produktion von Sauerstoffra-
dikalen, zu einem proinflammatorischen und pro-
thrombotischen Phänotyp des Endothels. Dies dürfte 
eine wichtige Bedeutung für die Entstehung der 
Atherosklerose und deren klinische Komplikationen, 
wie Herzinfarkt und Schlaganfall, haben. Die Induktion 
einer Endotheldysfunktion ist allen kardiovaskulären 
Risikofaktoren gemeinsam. Außerdem konnte in den 
letzten Jahren beobachtet werden, dass die kardio-
vaskulären Risikofaktoren zu einer verminderten Zahl 
und Funktion von zirkulierenden endothelialen Pro-
genitorzellen führen, was die endotheliale Reparatur-
kapazität beeinträchtigen kann.
Mehrere klinische Studien konnten zeigen, dass 
die Ausprägung der endothelialen Dysfunktion, in der 
Regel bestimmt als eingeschränkte endothelabhän-
gige Vasodilatation, mit der Entwicklung kardio-
vaskulärer Ereignisse eng assoziiert ist. Inwiefern eine 
Bestimmung der Endothelfunktion die Prädiktion des 
kardiovaskulären Risikos zusätzlich zu einer genauen 
Evaluation der bekannten kardiovaskulären Risikofak-
toren verbessern kann, wird gegenwärtig in mehreren 
Studien prospektiv untersucht. Dabei wird auch analy-
siert, inwiefern einfacher zu handhabende Messgeräte 
zur Bestimmung der Endothelfunktion (wie das Endo-
PAT-System) für die kardiovaskuläre Risikoprädiktion 
geeignet sind.
Gegenwärtig liefert die Bestimmung der Endo-
thelfunktion wertvolle Einblicke in die Pathophysiolo-
gie kardiovaskulärer Erkrankungen und ist geeignet, 
neue Therapiestrategien im Hinblick auf ihre vasku-
lären Effekte zu charakterisieren. Vor einem mög-
lichen Einsatz der Endothelfunktionsmessung in der 
klinischen Praxis zur Beurteilung des kardiovasku-
lären Risikos sollten die laufenden prospektiven Stu-
dien abgewartet werden, die den additiven Stellen-
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Introduction
The endothelium has been identified as a major regu-
lator of vascular tone and remodeling as well as arte-
rial inflammation and thrombosis, thus of key pro-
cesses of the atherosclerotic disease process. Impor-
tantly, endothelial dysfunction represents a common 
link of all known cardiovascular risk factors, such as 
dyslipidemia, smoking, diabetes, hypertension, obe-
sity, and mental stress. Endothelial dysfunction rep-
resents likely an important pathway, thereby cardio-
vascular risk factors promote the development and 
progression of vascular disease.
The crucial role of the endothelium for the regu-
lation of vasomotion was recognized by the experi-
ments of Robert Furchgott’s group [7], who later was 
awarded the Nobel prize in 1998 together with Louis 
Ignarro and Ferid Murad, who described the L-argi-
nine-nitric oxide-(NO-)cyclic guanosine monophos-
phate (cGMP) system as a major system mediating 
endothelium-dependent vasodilation. Endothelium-
derived NO activates the guanylate cyclase of vascu-
lar smooth muscle cells to promote cGMP-dependent 
vasodilation (Figure 1). This system is constantly ac-
tivated, in part by the shear stress caused by the blood 
flow over the endothelium, to keep the arteries in a 
dilated state. Interestingly, it has then been discov-
ered that endothelium-derived NO not only promotes 
endothelium-dependent vasodilation, such as during 
physical exercise, but has important anti-inflammato-
ry and antithrombotic effects, thereby actively sup-
pressing leukocyte adhesion and arterial thrombosis. 
Experimental studies could then confirm that endo-
thelium-derived NO prevents development of ath-
erosclerotic lesions [11], and can therefore be consid-
ered an important endogenous antiathero-genic sys-
tem.
Endothelial Functions
The Endothelium and Vascular Tone
Since the 1980s it has been well known that the endo-
thelium produces endothelium-derived relaxing fac-
tors (EDRFs) [7], and in the subsequent years, 
NO has been identified as a major EDRF [9, 17]. NO 
is synthesized by the action of the endothelial nitric 
oxide synthase (eNOS) mediating vasodilation, i.e., 
in response to shear stress. Several other stimuli, 
such as bradykinin and acetylcholine stimulate endo-
thelial NO synthesis, and have therefore been widely 
used to assess endothelium-dependent vasodilation 
(Figure 1).
Other important EDRFs include the endotheli-
um-derived hyperpolarizing factors (EDHFs), such 
as produced by the EDHF synthase cytochrome P450 
2C [5], that are particularly important mediators in 
the microcirculation. In addition, the cyclooxygen-
ase/prostacyclin synthase system of the healthy endo-
thelium releases the vasodilator prostacyclin.
The endothelium also produces vasoconstricting 
factors, such as endothelin, vasoconstricting pros-
tanoids, and angiotensin II, that can be increased un-
der pathophysiological conditions.
Notably, the healthy endothelium has an intact 
balance of the release of endothelium-derived vaso-
dilating factors, i.e., NO, prostacyclin and EDHFs, 
and endothelium-derived vasoconstricting factors, 
i.e., endothelin, angiotensin II and thromboxane A2.
On the other hand, under pathologic conditions, 
i.e., hypercholesterolemia, hypertension, coronary 
disease and smoking, the endothelium has a reduced 
availability of vasodilating factors, in particular NO, 
Figure 1. The L-arginine-nitric oxide (NO) system has been identified as an impor-
tant endogenous vasodilatory system. The endothelial NO synthase produces NO 
from the amino acid L-arginine. Endothelial release of NO, such as stimulated by 
increased blood flow, activates guanylate cyclase in vascular smooth muscle cells 
leading to vasodilation.
Abbildung 1. Das L-Arginin-Stickstoffmonoxid-(NO)-System konnte als ein wich-
tiges endogenes endothelabhängiges Vasodilatationssystem charakterisiert 
werden. Die endotheliale NO-Synthase produziert Stickstoffmonoxid unter 
Verwendung von L-Arginin als Substrat.  Das endothelial freigesetzte NO, 
z.B. durch den Blutfluss über dem Endothel stimuliert, aktiviert die Guanylat-
cyclase in den glatten Muskelzellen der Gefäßwand, was zur cGMP-abhängigen 
Vasodilatation führt.
wert der Endothelfunktionsanalyse zusätzlich zur 
genauen Beurteilung der bekannten kardiovaskulä-
ren Risikofaktoren im Hinblick auf die kardiovaskuläre 
Risikoprädiktion untersuchen.  
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and an augmented production of vasoconstricting 
factors, thereby impairing endothelium-dependent 
vasodilation, that is frequently assessed as “endothe-
lial function”.
The Endothelium and Vascular 
Inflammation
Atherosclerosis is considered a chronic vascular in-
flammatory disease today, and the activity of inflam-
mation (i.e., C-reactive protein [CRP] measurements) 
has been related to cardiovascular risk [8]. Endothelial 
dysfunction promotes arterial inflammation and vice 
versa, chronic inflammation promotes endothelial dys-
function (Figure 2). This concept has been nicely illus-
trated by a recent study in patients with chronic peri-
odontitis. After intense treatment of periodontitis as-
sociated with chronic inflammation, endothelial 
dysfunction was substantially improved, strongly sug-
gesting that chronic inflammation promotes endothe-
lial dysfunction [21]. Furthermore, in patients with 
coronary disease, endothelium-dependent vasodila-
tion was closely related to serum levels of CRP [4].
Vice versa, on the molecular level, endothelium-
derived NO production has been demonstrated to 
exert a major anti-inflammatory effect. Inhibition of 
eNOS stimulated the expression of leukocyte adhe-
sion molecules and chemokines, such as monocyte 
chemoattractant protein-1, promoting vascular 
monocyte infiltration [3, 18], that is considered an 
important step in atherosclerotic lesion formation. 
Likewise, pharmacological inhibition of endothelium-
derived NO production augmented endothelial adhe-
siveness of monocytes, further suggesting that a loss 
of endothelial NO availability promotes a pro-in-
flammatory phenotype of the endothelium.
The Endothelium and Arterial Thrombosis
A healthy intact endothelial monolayer actively in-
hibits arterial thrombus formation by several ways. 
First, an intact endothelial layer is critical for protec-
tion of circulating blood from exposure to prothrom-
botic subendothelial material and matrix. Then, a 
healthy endothelium releases several important me-
diators to actively prevent platelet activation, adhe-
sion, and aggregation. Notably, endothelium-derived 
NO limits platelet activation, adhesion and aggrega-
tion, and inhibits the expression of the prothrombotic 
protein plasminogen activator inhibitor-1 [14]. More-
over, platelets have been shown to express eNOS and 
to produce NO that likely limits recruitment of plate-
lets to the platelet-rich thrombus. An impaired plate-
let-derived production of NO has been suggested as 
an independent predictor of the acute coronary syn-
drome in patients with coronary disease [6]. Further-
more, endothelial prostacyclin production, largely 
dependent on COX-2, likely acts synergistically with 
NO to prevent platelet activation [15].
Endothelial Repair – Circulating Endothelial 
Progenitor Cells
In 1997, Asahara et al. reported the isolation of puta-
tive endothelial progenitor cells (EPCs) from human 
peripheral blood [1]. Subsequently, blood-derived 
EPCs were shown to contribute importantly to endo-
thelial repair [20] and ischemia-induced myocardial 
and peripheral neovascularization [10], and improved 
endothelial function [22].
Furthermore, several studies have demonstrat-
ed an impairment of bone marrow-derived EPC 
numbers and function in patients with cardiovascu-
lar risk factors as compared to healthy subjects, sug-
Figure 2. Cardiovascular risk factors and the inflammatory cascade act on the 
healthy endothelium to promote a pro-inflammatory and prothrombotic pheno-
type of the endothelium and impair the mobilization and function of endothelial 
progenitor cells (EPCs), mediated in part by a reduced endothelial cell and EPC ni-
tric oxide (NO) availability due to increased vascular and systemic oxidant stress. 
The altered endothelium leads to an impaired endothelium-dependent vasodila-
tion, and a pro-inflammatory and prothrombotic phenotype of the endothelium, 
promoting the development of atherosclerosis. Moreover, impaired EPC function 
alters the endogenous endothelial repair capacity.
Abbildung 2. Kardiovaskuläre Risikofaktoren und eine chronisch-entzündliche Ak-
tivierung führen zu einem proinflammatorischen und prothrombotischen Phäno-
typ des Endothels und beeinträchtigen die Mobilisierung und Funktion endothe-
lialer Progenitorzellen (EPCs), zumindest z.T. aufgrund einer Reduktion der endo-
thelialen und EPC-NO-Bioverfügbarkeit als Folge einer gesteigerten Produktion 
von Sauerstoffradikalen. Die proinflammatorische und prothrombotische Aktiv-
ierung des Endothels führt nicht nur zu einer beeinträchtigten endothelabhängi-
gen Vasodilatation, sondern begünstigt auch die Entwicklung und Progression 
der Atherosklerose. Die beeinträchtigte Funktion der EPCs vermindert sehr wahr-
scheinlich die endogene endotheliale Reparaturkapazität.
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gesting that cardiovascular risk factors impair the 
endogenous endothelial repair capacity. Moreover, 
reduced levels of circulating EPCs were closely as-
sociated with an increased risk of cardiovascular 
events in patients with coronary disease [19, 23].
At present, however, assessment of EPCs is not 
yet ready for clinical practical use for cardiovascular 
risk prediction, since the measurements are expen-
sive and time-consuming, need to be further stan-
dardized and simplified, and more prospective evi-
dence of an additional impact on cardiovascular risk 
prediction is required. Currently, EPCs are assessed 
in the research setting, where they provide impor-
tant novel insights into the pathophysiology of vas-
cular disease.
Methods for Assessment of “Endothelial 
Function”
Given the above observations, there has been an in-
tense interest in measurement of endothelial function 
in numerous clinical and experimental studies. Most 
studies have used the assessment of endothelium-
dependent vasodilation as an index of “endothelial 
function”. This is in part based on the observation 
that both, endothelium-dependent vasodilation and 
vasoprotective properties of the endothelium are me-
diated by NO, at least partly. The measurement of 
endothelium-dependent vasodilation, in particular in 
conductance arteries, therefore provides a good esti-
mate of the vascular NO availability.
Several methods to assess endothelium-depen-
dent vasodilation in humans have been developed 
over the last decades; among them, the most impor-
tant invasive tests are the evaluation of the change in 
coronary artery diameter and coronary blood flow 
after infusion of stimulants of endothelium-depen-
dent vasodilation, such as acetylcholine, during car-
diac catheterization. Later, Celermajer et al. have 
started the assessment of flow-dependent, endotheli-
um-mediated vasodilation by vascular ultrasound [2], 
a method that has since been widely used, because it 
is noninvasive, repeatable, reproducible and stan-
dardized among well-experienced laboratories. Im-
portantly, measurement of flow-dependent vasodila-
tion has also been shown to represent a good marker 
of vascular NO availability. This method is based on 
the increase in laminar shear stress by increased 
blood flow during reactive hyperemia, that results in 
a rapid activation of eNOS leading to vasodilation.
Endothelial Function Assessment 
and Prognosis
Given the important role of endothelial alterations in 
the development of vascular disease, numerous 
groups have studied the question of whether the de-
gree of endothelial dysfunction, as measured by im-
paired endothelium-dependent vasodilation of the 
coronary artery or the forearm circulation, is related 
to the risk of cardiovascular events in retrospective 
and some prospective studies. In all these studies, the 
degree of endothelial dysfunction was related to the 
risk of clinical cardiovascular events in the follow-up 
[12]. Lerman & Zeiher have further reported a multi-
variant meta-analysis of studies analyzing the associ-
ation between coronary or peripheral endothelial 
dysfunction and cardiovascular events (ten studies 
were included with a total of 2,500 subjects, 1–92 
months of follow-up) [13], strongly supporting the 
concept that endothelial dysfunction is also indepen-
dently associated with the risk of major cardiovascu-
lar events. Moreover, it has been shown that a higher 
degree of improvement of endothelial function after 
antihypertensive therapy was associated with a more 
favorable prognosis in postmenopausal women [16].
On this basis, endothelial function assessment 
could be reasonably supposed as an emerging adju-
vant test for the evaluation of “vulnerable” patients 
at high risk for future cardiovascular events. Howev-
er, before endothelial function measurements can be 
recommended in clinical practice, the ongoing pro-
spective studies analyzing the additive value of stan-
dardized endothelial function measurements to care-
ful cardiovascular risk prediction based on classic 
cardiovascular risk factors, such as the PREVENT-it 
study, should be awaited. Furthermore, the current 
methods for the assessment of endothelial function 
are time-consuming and require a highly qualified 
and experienced investigator to obtain reproducible 
results. Therefore, easier to handle systems, such as 
the Endo-PAT, are currently assessed in large clinical 
studies for their potential of additive cardiovascular 
risk prediction.
Conclusion
Endothelial dysfunction represents an early event in 
the development of atherosclerosis, and is induced by 
all known cardiovascular risk factors. Furthermore, 
numerous clinical studies have demonstrated a close 
relationship of the degree of endothelial dysfunction 
and the risk of cardiovascular events in the follow-up, 
suggesting that impaired endothelial function is rele-
vant also to the later stages of atherosclerotic vascular 
disease precipitating clinical events. Whether endo-
thelial function measurements can be used to improve 
cardiovascular risk prediction on top of a careful eval-
uation of classic cardiovascular risk factors is currently 
studied in large prospective clinical studies.
At present, endothelial function measurements, 
i.e., mostly the assessment of endothelium-dependent 
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vasodilation, is a highly valuable research tool to 
study mechanisms of vascular disease and to assess 
the impact of therapeutic interventions on vascular 
function. These measurements can provide impor-
tant information aiding in designing clinical outcome 
trials, that then ultimately prove the impact of thera-
peutic interventions on cardiovascular prognosis.
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